Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On January 12, 2022, Minerva Neurosciences, Inc. (the "Company") received a
deficiency letter (the "Nasdaq Letter") from The Nasdaq Stock Market LLC
("Nasdaq") notifying the Company that, for the last 30 consecutive business
days, the closing bid price of the Company's shares of common stock, $0.0001 par
value per share ("Common Stock"), has not been maintained at the minimum
required closing bid price of at least $1.00 per share, as required for
continued listing on the Nasdaq Global Market.
The Nasdaq Letter does not result in the immediate delisting of the Company's
Common Stock, and the Company's Common Stock will continue to trade
uninterrupted on the Nasdaq Global Market under the symbol "NERV."
In accordance with the listing rules of Nasdaq, the Company has been given 180
calendar days, or until July 11, 2022, to regain compliance with the minimum bid
price requirement. If at any time before July 11, 2022, the closing bid price of
the Company's Common Stock is at least $1.00 per share for a minimum of ten
consecutive business days, Nasdaq will provide written notification to the
Company that it complies with the minimum bid price requirement.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
MINERVA NEUROSCIENCES, INC. 
